Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Asthma (29)
  • Basic immunology (1)
  • x Biologicals (15)
  • Biomarkers (9)
  • COVID19 (2)
  • Drug allergy (3)
  • ENT (5)
  • Environmental allergy and climate change (1)
  • Immune deficiencies and autoimmunity (2)
  • Infections (3)
  • Mastocytosis and mast cells (1)
  • Microbiome (1)
  • Occupational allergy (2)
  • Pediatrics (10)
Poster available until
Poster categories
  • Thematic Poster Session (1)
keywords
Session Reference
  • L-TPS02 (9)
  • L-TPS07 (11)
  • L-TPS08 (1)
  • L-TPS09 (3)
  • L-TPS10 (1)
  • L-TPS19 (1)
  • L-TPS21 (1)
  • TPS06 (8)
  • TPS09 (2)
  • TPS17 (4)
  • TPS18 (9)
  • TPS29 (1)
  • TPS51 (1)
  • TPS52 (5)
  • x TPS55 (10)
  • x TPS56 (5)
  • TPS57 (1)
  • TPS63 (1)
  • TPS67 (9)
  • TPS69 (2)
15 results
Thumbnail

- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience

Thumbnail

- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study

Thumbnail

- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report

Thumbnail

- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry

Thumbnail

- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma

Thumbnail

D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Thumbnail

- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs

Thumbnail

- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life

Thumbnail

- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab

Thumbnail

- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics

Thumbnail

- D3.114 - Does severe asthma exist in preschool children?

Thumbnail

- D3.116 - Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis

Thumbnail

- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice

Thumbnail

- D3.119 - Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype

Thumbnail

- D3.123 - Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM